FDA warned Swadesii that its website sells unapproved drugs with claims to treat serious conditions including measles, cancer and Alzheimer's.
What happened
FDA reviewed https://swadesii.com/ in September 2025 and found the website offered Swadesii products for sale in the United States. FDA said the product labeling included claims to cure, mitigate, treat, or prevent serious and/or life-threatening conditions such as measles, cancer, diabetes, stroke, Alzheimer's, and hepatitis. FDA also said the ophthalmic product Elaneer Kuzhambu is especially concerning because eye administration bypasses some of the body's natural defenses.
What FDA found
The website offers unapproved new drugs for sale in the United States without FDA-approved applications.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The product labeling includes claims to cure, mitigate, treat, or prevent diseases, which makes the products drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128The products are not generally recognized as safe and effective for their labeled uses and are therefore new drugs.
FD&C Act section 201(p), 21 U.S.C. 321(p)The homeopathic products are still subject to drug approval, adulteration, and misbranding requirements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)Elaneer Kuzhambu is an unapproved ophthalmic drug product, which is especially concerning because eye products bypass some natural defenses.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
Notify FDA in writing within 15 working days of the specific steps taken to correct the violations, explain steps to prevent recurrence, and include related documentation. If the company believes the products are not violations, it must include its reasoning and supporting information.
Who should pay attention
- online sellers of Ayurvedic and homeopathic products
- brands and importers that make disease-treatment claims
- consumers using such products for serious conditions
This is a summary. Read the original letter on fda.gov.